

1 **Supplementary Information**

2 **A distinct sortase SrtB anchors and processes a streptococcal adhesin**

3 **AbpA with a novel structural property**

4 Xiaobo Liang^{a,1,2}, Bing Liu^{b,1}, Fan Zhu^{a,1}, Frank A. Scannapieco^c, Elaine M
5 Haase^c, Steve Matthews^{b*} and Hui Wu^{a*}

6 ^aDepartments of Pediatric Dentistry and Microbiology, University of Alabama
7 at Birmingham School of Dentistry, Birmingham, AL , USA; ^bDepartment of
8 Life Sciences, Imperial College London, London, UK; ^cDepartment of Oral
9 Biology, University at Buffalo, Buffalo, NY, USA

10 **Key words:** sortase, amylase binding protein A, LPXTG motif,
11 streptococcus

12 **Running Title:** New sortase and adhesin substrate system

13
14
15
16 ¹ These three authors contribute equally to the manuscript

17 ² Present Address: Yunnan Institute of Food Safety, Kunming University of
18 Science and Technology, Kunming, Yunnan, China.

19 * To whom correspondence should be addressed. E-mail: hwu@uab.edu or
20 s.j.matthews@imperial.ac.uk

1 **Methods**

2 **Bacterial strains, plasmids and growth conditions**

3 The bacterial strains and plasmids used in this study are listed in SI Table 1.

4 *Escherichia coli*, *S. parasanguinis* and *S. gordonii* strains were cultured in the
5 growth conditions described previously¹. For bacterial growth, 100 µg ml⁻¹
6 ampicillin, 50 µg ml⁻¹ kanamycin or 300 µg ml⁻¹ erythromycin were used in *E.*
7 *coli*, 125 µg ml⁻¹ kanamycin or 5 µg ml⁻¹ erythromycin were used in *S.*
8 *parasanguinis*, 1 mg ml⁻¹ kanamycin or 5 µg ml⁻¹ erythromycin were used in *S.*
9 *gordonii*.

10 ***Molecular cloning techniques***

11 *E. coli* plasmid DNA was isolated using the mini-prep DNA preparation kit
12 (Qiagen). The genomic DNA of *S. parasanguinis* and *S. gordonii* were
13 extracted using the Puregene DNA isolation kit (Gentra System). Polymerase
14 chain reaction (PCR) was performed with KOD hot start DNA polymerase
15 (Novagen), using the GeneAmp PCR system 9700 (PE Applied Biosystems).
16 Primers used for the amplification of DNA fragments are listed in SI Table 2.
17 Restriction enzymes and T4 DNA ligase (New England Biolabs) were used
18 according to the manufacturer's instructions. Competent *E. coli* cells were
19 prepared and transformed by standard techniques ². *S. parasanguinis* was
20 transformed by electroporation using a gene pulser (Bio-Rad Laboratories) as
21 described previously³. *S. gordonii* was transformed by natural transformation
22 method ⁴.

23 **Construction of *srtA* and *srtB* mutants and complementation strains in** 24 ***S. parasanguinis***

1 The allelic replacement strategy was used in *srtA* and *srtB* mutagenesis. *srtA*
2 and *srtB* and their flanking regions were amplified from *S. parasanguinis*
3 FW213 genomic DNA by PCR with primer pairs *srtA*-F1/*srtA*-R1 and *srtB*-
4 F1/*srtB*-R1, respectively. PCR products were cloned into *Hind*III and *Xho*I
5 digested and end-blunted pSU21⁷, yielding pBYL12 (containing *srtA*) and
6 pBYL11 (containing *srtB*) respectively. Inverse PCR with two primer pairs of
7 *srtA*-F2/*srtA*-R2 and *srtB*-F2/*srtB*-R2, in each of which the *Bgl*II and *Bam*HI
8 enzyme sites were introduced. The resulting DNA fragments were digested
9 with *Bgl*II or *Bam*HI and ligated with the *Bam*HI digested erythromycin
10 resistance gene fragment to generate pBYL16 and pBYL17, respectively.
11 These plasmids were transformed into *S. parasanguinis* FW213 and the
12 erythromycin resistance transformants BYL32 and BYL31 were isolated,
13 confirmed by colony PCR and were used in the study.

14 The *srtB* complement strain was constructed using plasmid pDL276.
15 Briefly, the full length *srtB* gene was amplified from *S. parasanguinis* using the
16 primer pair *srtB*-F3/*srtB*-R3, in which *Sac*I and *Sph*I were introduced. The
17 PCR product was digested with *Sac*I and *Sph*I and was inserted into same
18 enzymes digested pDL276, yielding plasmid pBYL37. This plasmid was
19 transformed into BYL31 and the colonies resistant to both kanamycin and
20 erythromycin were confirmed and named as BYL37.

21 **Construction of *srtB* mutant and complementation strains in *S. gordonii***

22 A 2202-bp PCR fragment of *srtB* was amplified from *S. gordonii* using the
23 primer pair, *srtB*-F1g/*srtB*-R1g, and then cloned into the pGEM-T easy vector.
24 The resulting construct was used as template, inverse PCR were performed
25 with the primer pair *srtB*-F2g/*srtB*-R2g, in which *Hind*III site was introduced.
26 The resulting PCR product was digested with *Hind*III and ligated in-frame with
27 a same enzyme digested promoterless kanamycin resistance cassette *aphA3*
28 to generate the plasmid pAL824. Through the inverse PCR, a 531-bp DNA

1 fragment which coding the 16-193 amino acids of SrtB protein was deleted.
2 This plasmid was used to transform *S. gordonii* and the kanamycin resistance
3 transformants were isolated, confirmed by PCR and sequence analyses and
4 was named as AL825.

5 The complement strain was constructed using pVPT-gfp vector. *srtB* gene
6 was PCR amplified from the genomic DNA of *S. gordonii*, using the primer pair
7 *srtB*-F3g/*srtB*-R3g with engineered *Sal*I and *Bam*HI restriction enzyme sites.
8 The PCR product was digested with *Sal*I and *Bam*HI, and cloned into pVPT-
9 *gfp*⁸ to generate pAL826. This plasmid was transformed into the *abpA* mutant
10 AL825 to construct complemented strains AL827.

11 **Cross-complementation of *srtB* mutation between *S. parasanguinis* and** 12 ***S. gordonii***

13 To test if the SrtB from *S. parasanguinis* is functional in *S. gordonii* and vice
14 versa, two cross-complementation strains were constructed. The *S. gordonii*
15 *srtB* was amplified with the primer pair *srtB*-F4g/*srtB*-R4g and was cloned into
16 pDL276. The resulting plasmid (pAL828) was transformed into *S.*
17 *parasanguinis* mutant BYL31 to generate AL829. Similarly, the *S.*
18 *parasanguinis srtB* was amplified with the primer pair *srtB*-F4/*srtB*-R4 and was
19 cloned into pVPT-*gfp*. The resulting plasmid (pAL830) was transformed into *S.*
20 *gordonii* mutant AL825 to generate AL831. AL829 and AL831 were used in
21 amylase binding assays.

22 **Functional study of SrtB of *S. aureus* and *S. pneumoniae***

23 For the in vivo studies, two *srtB* cross complementation strains were
24 constructed. Briefly, *srtB* was amplified by PCR from *S. aureus* COL and *S.*
25 *pneumoniae* Tigr4 genome respectively using the primer pairs of *srtB*-
26 F1c/*srtB*-R1c and *srtB*-F1t/*srtB*-R1t. The PCR products were digested with
27 *Sph*I/*Eco*RI and ligated with pDL276. The resulting plasmids (pAL829 and

1 pAL831) were transformed into *S. parasanguinis* *srtB* mutant to generate two
2 cross-complementation strains, AL838 and AL839. The strains were used in
3 amylase binding assays.

4 For the in vitro studies, two recombinant SrtB proteins were expressed in *E.*
5 *coli*. Primer pair of *srtB*-F2c/*srtB*-R2c and *srtB*-F2t/*srtB*-R2t was used in PCR
6 to amplify *srtB* from *S. aureus* COL and *S. pneumoniae* Tigr4 genome
7 respectively. The PCR product was digested with *Bam*HI/*Sac*I and ligated with
8 pET28a-sumo, and the resulting plasmids were transformed into *E. coli* BLR.
9 Recombinant SrtB were expressed, purified and used in the enzymatic assay
10 with the recombinant AbpA as a substrate.

11 **Construction of *abpA* deletion mutants and site-directed mutants in *S.*** 12 ***parasanguinis***

13 Using *abpA*-F3 as a forward primer, in combination with different reverse
14 primers, deletion and site-directed mutation alleles for the conserved C-
15 terminal cell wall sorting signal motif of AbpA were generated by PCR
16 amplification. The primers used are listed in SI Table2. The PCR products
17 were digested with *Sal*I and *Kpn*I, ligated with same enzymes digested pVPT-
18 *gfp*, yielding the mutation plasmids. These plasmids were then transformed
19 into the *abpA* mutant strain AL821. The resulting strains were used in amylase
20 binding assays.

21 **Preparation of polyclonal antibody against AbpA**

22 1.0 mg of the purified AbpA of *S. parasanguinis* was used to generate
23 polyclonal antisera in rabbit by Cocalico Biologicals, Inc (Reamstown, PA,
24 USA). The titer and the specificity of the antiserum to AbpA were tested by
25 ELISA and western blot analysis, respectively.

26 **Construction of AbpA-GFP swap strains in *S. parasanguinis***

1 Using pAL822 as a template, we performed inverse PCR with a forward
2 primer abpA-F and three different abpA-R primers (abpA-R1, -R2 and -R3
3 designed for swap1, 2 and 3 construct respectively), in which the *SphI* and
4 *XhoI* sites were introduced. At the same time *gfp* was amplified from pVPT-gfp
5 with the primer pair gfp-F/gfp-R which also contains *SphI* and *XhoI* sites. Both
6 PCR products were digested with *SphI* and *XhoI* and ligated together to
7 produce plasmid pAL834 and its variants, in which the *gfp* gene was inserted
8 between the coding sequence of the N-terminal signal peptide and the C-
9 terminal cell wall anchor motif of AbpA. These plasmids were transformed into
10 *S. parasanguinis* to obtain AbpA-GFP swap strains, Swap1, Swap2 and
11 Swap3. Another strain (SP-GFP) in which GFP was fused only with the N-
12 terminal conserved domain of AbpA. This strain was constructed similarly and
13 used as a control.

14 **In vitro enzyme activity assay of SrtB**

15 Recombinant AbpA, AbpA-His or AbpA-Gfp and SrtB or SrtB-His were
16 incubated together in 37°C for 1 h and then probed with anti-AbpA or anti-His
17 to detect cleavage during the reaction. The resulting AbpA peptides were
18 identified with Mass Spectrometric analyses and N-terminal amino acid
19 sequencing (University of Texas Medical Branch Biomolecular Resource
20 Facility).

21 **SDS-PAGE and Western blot analysis**

22 Protein samples were separated on 10% SDS-polyacrylamide gel and then
23 stained with Coomassie blue staining R-250. For Western blot analysis, the
24 separated proteins were transferred to nitrocellulose membranes. The
25 membranes were blocked by 5% skimmed milk in PBS for 1 h prior to probing

1 with AbpA and other antibodies diluted at 1:2000 in PBS with 0.1% Tween-20.
2 Horseradish peroxidase-conjugated anti-rabbit and ECL Western blot
3 detection reagents (GE Healthcare) were used to detect AbpA and other
4 proteins.

5 **Figure Legends**

6 **Supplementary Figure S1.** Conservation and uniqueness of AbpA. **A.**

7 Comparison of *abpA-srtB* gene locus among different oral streptococcal
8 species. **B.** Alignment of deduced protein sequence of AbpA homologs. The
9 N-terminal and C-terminal conserved motifs were marked by black rectangle.

10 Secondary structure is shown above the alignment; β -strands (β 1-3) are
11 colored as yellow arrows and the five helices (α 1-5) as red rectangles. **C.**

12 Schematic representation of typical CWSS and C terminus of AbpA. +,
13 positively charged tail.

14

15 **Supplementary Figure S2.** NMR titration of AbpA with amylase. **A.** ^1H - ^{15}N

16 HSQC spectra of *S. parasanguinis* AbpA collected in the absence (left) and
17 presence (middle - 0.5 molar ration and right - 1 molar ratio) of human α -

18 amylase. **B.** Amylase titration for mutant AbpA variants. ^1H - ^{15}N HSQC spectra

19 of *S. parasanguinis* AbpA mutant proteins collected in the absence (black) and
20 presence (red) of a 5-fold excess of human α -amylase. From left to right:

21 KK37/38A, YY132/133A and VL117/118A.

22

1 **Supplementary Table S1.** Bacterial strains and plasmids used in this study.

Strain or plasmid	Relevant characteristics	Reference or source
Strains		
<i>E. coli</i>		
Top10	F ⁻ <i>mcrA</i> Δ(<i>mrr-hsdRMS-mcrBC</i>) φ80 <i>lacZ</i> ΔM15 Δ <i>lacX74 nupG recA1 araD139</i> Δ(<i>ara-leu</i>)7697 <i>galE15 galK16 rpsL</i> (Str ^r) <i>endA1 λ⁻</i>	Invitrogen
BLR(DE3)	F ⁻ <i>ompT hsdS_B</i> (r _B ⁻ m _B ⁻) <i>gal dcm</i> (DE3) Δ(<i>srl – recA</i>)306::Tn10 (Tet ^r).	Novagen
BL21(DE3)	<i>huA2 [lon] ompT gal</i> (λ DE3) [<i>dcm</i>] Δ <i>hsdS λ DE3 = λ sBamHlo ΔEcoRI-B</i> <i>int::(lacI::PlacUV5::T7 gene1) i21 Δnin5</i>	NEB
AL832	BLR(DE3) with pAL832 plasmid; Kan ^r	This study
AL833	BLR(DE3) with pAL833 plasmid; Kan ^r	This study
AL840	BL21(DE3) with pAL840 plasmid; Kan ^r	⁹
AL841	BL21(DE3) with pAL841 plasmid; Kan ^r	This study
AL842	BL21(DE3) with pAL842 plasmid; Kan ^r	This study
AL843	BL21(DE3) with pAL843 plasmid; Kan ^r	This study
AL844	BL21(DE3) with pAL844 plasmid; Kan ^r	This study
AL845	BL21(DE3) with pAL845 plasmid; Kan ^r	This study
AL846	BL21(DE3) with pAL846 plasmid; Kan ^r	This study
<i>S. parasanguinis</i>		
FW213	<i>S. parasanguinis</i> parent strain	¹⁰
AL821	FW213 <i>abpA::aphA3</i> ; Kan ^r	This study
AL823	FW213 <i>abpA::aphA3::pAL822</i> ; Kan ^r , Em ^r	This study
BYL31	FW213 <i>srtB::emr</i> , Em ^r	This study
BYL32	FW213 <i>srtA::emr</i> , Em ^r	This study
BYL37	FW213 <i>srtB::emr::pBYL37</i> ; Em ^r , Kan ^r	This study
AL829	FW213 <i>srtB::emr::pAL828</i> ; Em ^r , Kan ^r	This study
AL835	FW213::pAL834; Em ^r	This study
AL837	FW213::pAL836; Em ^r	This study
AL838	FW213 <i>srtB::emr::pAL829</i> ; Em ^r , Kan ^r	This study
AL839	FW213 <i>srtB::emr::pAL831</i> ; Em ^r , Kan ^r	This study
<i>S. gordonii</i>		
Challis	<i>S. gordonii</i> parent strain	¹¹

AL825	Challis <i>srtB</i> :: <i>aphA3</i> ; Kan ^r	This study
AL827	Challis <i>srtB</i> :: <i>aphA3</i> ::pAL826; Kan ^r , Em ^r	This study
AL831	Challis <i>srtB</i> :: <i>aphA3</i> ::pAL830; Kan ^r , Em ^r	This study
Plasmids		
pGEM-T	Commercial TA cloning vector	Promega
pVPT-gfp	<i>E. coli</i> & <i>Streptococcus</i> shuttle vector	⁸
pDL276	<i>E. coli</i> & <i>Streptococcus</i> shuttle vector	¹²
pET28a-sumo	<i>E. coli</i> expression vector with a SUMO tag	¹³
pSU21	<i>E. coli</i> cloning vector	⁷
pAL820	pGEM- <i>abpA-aphA3</i>	This study
pAL822	pVPT- <i>abpA</i>	This study
pBYL16	pSU21- <i>srtA-emr</i>	This study
pBYL17	pSU21- <i>srtB-emr</i>	This study
pBYL37	pDL276- <i>srtB</i>	This study
pAL824	pGEM- <i>srtB(g)</i> ^a - <i>aphA3</i>	This study
pAL826	pVPT- <i>srtB(g)</i>	This study
pAL828	pDL276- <i>srtB(g)</i>	This study
pAL829	pDL276- <i>srtB(c)</i>	This study
pAL830	pVPT- <i>srtB</i>	This study
pAL831	pDL276- <i>srtB(t)</i>	This study
pAL832	pET28a- <i>abpA</i>	This study
pAL833	pET28a-sumo- <i>srtB</i>	This study
pAL834	pVPT- <i>abpA-gfp</i>	This study
pAL840	pET28a-sumo- <i>abpAΔC10aa</i>	⁹
pAL841	pET28a-sumo- <i>abpA(24-138aa)</i>	This study
pAL842	pET28a-sumo- <i>abpA(139-207aa)</i>	This study
pAL843	pET28a-sumo- <i>abpA-KK37/38A</i>	This study
pAL844	pET28a-sumo- <i>abpA-YY132/133A</i>	This study
pAL845	pET28a-sumo- <i>abpA-VL117/118A</i>	This study
pAL846	pET28a- <i>srtB</i>	This study

1 ^ag means this gene comes from *S. gordonii* CH1, c means this gene comes

2 from *S. aureus* Col, t means this gene comes from *S. pneumoniae* Tigr4

1 **Supplementary Table S2.** Primers used in this study

Primer	Sequence ^b
abpA-F1	GGGCACGTAAGTTAGCTGAGTT
abpA-R1	TGAATCAGGGATTTGACGAAGATAAAGGT
abpA-F2	CCTGAATTCCAATACAGGTGCTGCTGCAGCAAATACTGCAAGAGCTG
abpA-R2	CTCGAATTCGTTGACAAAGACGGTAAAACAG
abpA-F3	ATCGTTCGACATGAAAAAAGTTTTATTATCATCAGTAGC
abpA-R3	CATGGTACCAAATTATTTAACTGCGCTTGTTTTGGA
abpA-F4	GCACCATGGCTATGAAAAAAGTTTTATTATCATCAGTAG
abpA-R4	ATACTCGAGTTTAACTGCGCTTGTT
abpA-del1	CATGGTACCAAATTAACCAGCTTTAGCATCAGCC
abpA-del2	CATGGTACCAAATTAAGCTTTACCAGCTTTAGC
abpA-del3	CATGGTACCAAATTAGCTTGTTTTGGAAGAGC
abpA-L/N	CATGGTACCAAATTATTTAACTGCGCTTGTTTTGGATTAGCTTTACCAG
abpA-L/R	CATGGTACCAAATTATTTAACTGCGCTTGTTTTGGACGAGCTTTACCAG
abpA-P/A	CATGGTACCAAATTATTTAACTGCGCTTGTTTTAGCAAGAGCTTTACCAG
abpA-P/D	CATGGTACCAAATTATTTAACTGCGCTTGTTTCATCAAGAGCTTTACCAG
abpA-K/E	CATGGTACCAAATTATTTAACTGCGCTTGTTCTGGAAGAGCTTTACCAG
abpA-K/L	CATGGTACCAAATTATTTAACTGCGCTTGTTAGTGGAAGAGCTTTACCAG
abpA-T/A	CATGGTACCAAATTATTTAACTGCGCTTGCTTCTGGAAGAGCTTTACCAG
abpA-T/S	CATGGTACCAAATTATTTAACTGCGCTTGATTTTGGGAAGAGCTTTACCAG
abpA-S/W	CATGGTACCAAATTATTTAACTGCCCATGTTTTTGGGAAGAGCTTTAC
abpA-S/G	CATGGTACCAAATTATTTAACTGCCCTGTTTTTGGGAAGAGCTTTAC
abpA-S/R	CATGGTACCAAATTATTTAACTGCCCTTGTTTTTGGGAAGAGCTTTAC
abpA-K37/38A F	CTGCTGCATCACGCCATGAAACATATGCCGCTTGATCAATTGGTTAGATGCACTTG
abpA-K37/38A R	CAAGTGCATCTAACCAATTGATCCAAGCGGCATATGTTTCATGGCGTGATGCAGCAG
abpA-H56AF	CTTCTTTGATTTCTGCTTCAGCAGCTGCTACTTGAGTGTTAGCTT
abpA-H56AR	AAGCTAACACTCAAGTAGCAGCTGCTGAAGCAGAAATCAAAGAAG
abpA-Y114A F	ATTTTTGTTGAAGAACTTGGATGGCACGGTTGCGAACTGTGTTGTATG
abpA-Y114A R	CATACAACACAGTTCGCAACCGTGCCATCCAAGTTCCTCAACAAAAAT
abpA-VL117/118AA F	GCAGCTTCAATGTATTTTTGTTGAGCAGCTTGATGTAACGGTTGCGAACTG
abpA-VL117/118AAR	CAGTTCGCAACCGTTACATCCAAGCTGCTCAACAAAAATACATTGAAGCTGC
abpA-Y132/133AF	TTAGCTTCTACAGCTGTTTCATCGGCGGCGTTACCTTGAGCTTTAGCAGCTTC
abpA-Y132/133AR	GAAGCTGCTAAAGCTCAAGGTAACGCCGCGATGAAACAGCTGTAGAAGCTAA
abpA-V138A F	CATTTGTACGGTTAGCTTCTGCAGCTGTTTCATCGTAGTAG
abpA-V138A R	CTACTACGATGAAACAGCTGCAGAAGCTAACCGTACAAATG
AbpA-138aaR	ATGCCTCGAG TACAGCTGTTTCATCGTAGTAG
AbpA-24aaF	ATGCGGATCCCAAGGTGAAAACCCAAGTG

AbpA-139aaF	ATGC <u>GGATCC</u> GAAGCTAACCGTACAAATGAA
abpA-207aaR	GACAC <u>CTCGAG</u> TATTAACTGCGCTTG
srtA-F1	GTCAAACGGACCAATGTAG
srtA-R1	CGTACATAATTTCTCCTCAC
srtB-F1	GCACCTGTATTTGCACAAGG
srtB-R1	CTTCGTTTGCCCATCTTCG
srtA-F2	TGGGGG <u>GAGATCT</u> ATCTTCTAGCACAGCT
srtA-R2	TTTCTCAGC <u>AGATCT</u> CATTTCAATTGAT
srtB-F2	CTCGAC <u>GGATCC</u> CGTCATCAATGCCC
srtB-R2	GCAACGATGTTGAGGATCCTATTGCGTAAAC
srtB-F3	TTT <u>GAGCTCT</u> AATTAGCTCGAAACGAATATCA
srtB-R3	TTAGCATGCATTTCTTACAAATACTAGACATA
srtB-F4	ATAC <u>GTTCGAC</u> ATGAAAAGAGCTGAGA
srtB-R4	CTA <u>AGGATCCT</u> TGTTGACCACGTGTT
srtB-F5	ATCGGATCCATGAAAAGAGCTGAGA
srtB-R5	AATCTCGAGTTATTATTGTTGACCA
srtB-F1g c	AGTTTTATTGTCAAGCGTG
srtA-R1g	ATAAACAATCCAGCGC
srtB-F2g	ATCGGATCCTCTTATTTGGAGCCTT
srtB-R2g	CATGGATCCATGGGCTTGTTATTG
srtB-F3g	ACCGT <u>TCGAC</u> ATGAGTCAAATGCTA
srtB-R3g	TCAGGGGATCCCTATCTAGTAGGAGTATAT
srtB-F4g	AGTGCATGCGATGAGTCAAATGCTA
srtB-R4g	TCTGAATTCCTATCTAGTAGGAGTA
srtB -F1c	ATTGCATGCAGATGAGAATGAAGCGATTTTT
srtB-R1c	ACTGAATTCCTAACTTACCTTAATTATTTTTG
srtB -F2c	AGTGGATCCATGAGAATGAAGCGATTTTT
srtB-R2c	GATGAGCTCTTATTAACCTTACCTTAATTATTTTTG
srtB-F1t	ATTGCATGCAGATGGCGGTAATGGCGTATCC
srtB-R1t	ACTGAATTCCTACTGTTGTCCATCCTCCACCT
srtB-F2t	AGTGGATCCATGGCGGTAATGGCGTATCC
srtB-R2t	GATGAGCTCTTATTACTGTTGTCCATCCTCCACCT

- 1 ^a Restriction sites are underlined.
- 2 ^b g stands for *S. gordonii* CH1, c for *S. aureus* COL, t for *S. pneumoniae*
- 3 Tigr4
- 4
- 5

1

Supplementary Table S3.

2

Summary of mutagenesis at the C-terminal domain of AbpA.


Mutations	Sequences	Description	Amylase binding
WT	KAGKALPKTSAVK		+
Del1(205-207)	KAGKALPKTS		-
Del2(200-207)	KAGKA		-
Del3(195-207)	-		-
200L/N	KAGKAN <u>P</u> PKTSAVK	Hydrophobic/uncharged	-
200L/R	KAGKAR <u>P</u> PKTSAVK	Hydrophobic/Hydrophilic	-
201P/A	KAGKAL <u>A</u> KTSAVK	Hydrophobic/Hydrophobic	-
201P/D	KAGKAL <u>D</u> KTSAVK	Hydrophobic/Hydrophilic	-
202K/E	KAGKALP <u>E</u> TSAVK	Hydrophilic/Hydrophilic	+
202K/L	KAGKALP <u>L</u> TSAVK	Hydrophilic/Hydrophobic	-
203T/A	KAGKALPK <u>A</u> SAVK	Uncharged/Hydrophobic	-
203T/S	KAGKALPK <u>S</u> SAVK	Uncharged/Uncharged	-
204S/W	KAGKALPKT <u>W</u> AVK	Uncharged/Hydrophobic	+
204S/G	KAGKALPKT <u>G</u> AVK	Uncharged/Hydrophobic	+
204S/R	KAGKALPKT <u>R</u> AVK	Uncharged/Hydrophilic	+

3



4

References

- 1 Wu, H., Zeng, M. & Fives-Taylor, P. The glycan moieties and the N-terminal polypeptide backbone of a fimbria-associated adhesin, Fap1, play distinct roles in the biofilm development of *Streptococcus parasanguinis*. *Infect Immun* **75**, 2181-2188 (2007).
- 2 J. Sambrook, E.F. Fritsch & T. Maniatis. *Molecular cloning: a laboratory manual*. Vol. 2 (Cold Spring Harbor Laboratory Press, 1989).
- 3 Fenno, J. C., Shaikh, A. & Fives-Taylor, P. Characterization of allelic replacement in *Streptococcus parasanguis*: transformation and homologous recombination in a 'nontransformable' streptococcus. *Gene* **130**, 81-90 (1993).
- 4 Petersen, F. C. & Scheie, A. A. Natural transformation of oral streptococci. *Methods Mol Biol* **666**, 167-180 (2010).
- 5 Kremer, B. H. *et al.* Characterization of the sat operon in *Streptococcus mutans*: evidence for a role of Ffh in acid tolerance. *Journal of bacteriology* **183**, 2543-2552, doi:10.1128/jb.183.8.2543-2552.2001 (2001).
- 6 Zhou, M., Fives-Taylor, P. & Wu, H. The utility of affinity-tags for detection of a streptococcal protein from a variety of streptococcal species. *Journal of microbiological methods* **72**, 249-256, doi:10.1016/j.mimet.2007.12.002 (2008).
- 7 Bartolome, B., Jubete, Y., Martinez, E. & de la Cruz, F. Construction and properties of a family of pACYC184-derived cloning vectors compatible with pBR322 and its derivatives. *Gene* **102**, 75-78 (1991).
- 8 Zhou, M., Fives-Taylor, P. & Wu, H. The utility of affinity-tags for detection of a streptococcal protein from a variety of streptococcal species. *J Microbiol Methods* **72**, 249-256 (2008).
- 9 Liu, B., Zhu, F., Wu, H. & Matthews, S. NMR assignment of the amylase-binding protein A from *Streptococcus parasanguinis*. *Biomolecular NMR assignments* **9**, 173-175, doi:10.1007/s12104-014-9568-9 (2015).
- 10 Cole, R. M., Calandra, G. B., Huff, E. & Nugent, K. M. Attributes of potential utility in differentiating among "group H" streptococci or *Streptococcus sanguis*. *J Dent Res* **55**, A142-153 (1976).
- 11 Rogers, J. D. *et al.* Identification and analysis of a gene (abpA) encoding a major amylase-binding protein in *Streptococcus gordonii*. *Microbiology* **144** (Pt 5), 1223-1233 (1998).
- 12 Dunny, G. M., Lee, L. N. & LeBlanc, D. J. Improved electroporation and cloning vector system for gram-positive bacteria. *Appl Environ Microbiol* **57**, 1194-1201 (1991).
- 13 Zhu, F. *et al.* Structural and functional analysis of a new subfamily of glycosyltransferases required for glycosylation of serine-rich streptococcal adhesins. *The Journal of biological chemistry* **286**, 27048-27057, doi:10.1074/jbc.M110.208629 (2011).

A

B






C

LPXTG	Hydrophobic domain	+
--------------	--------------------	----------

Classic CWSS

LPKTS	AVK
--------------	------------

C terminus of AbpA

A**B**